



## Metformin – Safety update

- On February 3, 2020, the [FDA announced](#) that they posted [laboratory results](#) showing N-Nitrosodimethylamine (NDMA) levels in some metformin products approved in the U.S. They have determined that the levels of NDMA in metformin products tested range from not detectable to low levels.
- The FDA has not recommended metformin recalls to date.
- Metformin is used to control high blood sugar in patients with type 2 diabetes.
- Patients should continue taking metformin to keep their diabetes under control. It could be dangerous for patients with this serious condition to stop taking their metformin without first talking to their health care professionals.
- The FDA plans to post the methods used in laboratory testing of metformin in the near future. The FDA is also collaborating with international regulators to share testing results for metformin, along with testing results for other drugs.
- The FDA will continue to monitor NDMA in metformin, along with other drug products, and will provide timely updates of new developments, including product recalls. For more information about NDMA, visit the FDA's [nitrosamines](#) webpage.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.